Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children's hospital.
Antibodies, Anticardiolipin
/ blood
Anticoagulants
/ therapeutic use
Beijing
Chest Pain
Child
Child, Preschool
Female
Fibrin Fibrinogen Degradation Products
/ analysis
Hospitals, Pediatric
Humans
Male
Mycoplasma pneumoniae
/ pathogenicity
Pneumonia, Mycoplasma
/ complications
Prognosis
Retrospective Studies
Thrombosis
/ drug therapy
Tomography, X-Ray Computed
Treatment Outcome
Children
Mycoplasma pneumoniae
Pneumonia
Severe
Thrombosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Jan 2020
16 Jan 2020
Historique:
received:
26
10
2019
accepted:
07
01
2020
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
31
3
2020
Statut:
epublish
Résumé
With the increase of awareness of mycoplasma pneumoniae pneumonia (MPP), we found thrombosis in severe MPP (SMPP) was not rare. The aim of the study was to investigate the clinical characteristics, treatment, and long-term prognosis of MPP-associated thrombosis. We retrospectively reviewed the medical records of 43 children with MPP-associated thrombosis between January 2013 and June 2019 at Beijing Children's Hospital. The results of blood coagulation studies, autoimmune antibody, thrombophilia screening, contrast-enhanced lung computed tomography, echocardiography, and blood vessel ultrasonography were analyzed, as were treatment outcomes. Forty-two patients were diagnosed with SMPP. D-dimer was higher than 5.0 mg/L in 58.1% (25/43) of patients. The mean D-dimer level was 11.1 ± 12.4 mg/L. Anticardiolipin-IgM was positive in 60.0% of patients, β2-glycoprotein-IgM in 64.0%, and lupus anticoagulant in 42.1%. Chest imaging revealed pulmonary consolidation with lobe distribution in all patients (2/3-1 lobe in 10 patients, > 1 lobe in 29 patients). In our experience, thrombosis can occur in a vessel of any part of the body, and it can be initially detected as late as 31 days after disease onset. Thrombosis in the brain and abdomen can occur early, at 5 days after disease onset. Pulmonary vessels were the most commonly involved sites in the current study, and accordingly chest pain was the most common symptom (32.6%), followed by neurological symptoms (14.0%) and abdominal pain (9.3%). Thirty-five percent of patients were asymptomatic with regard to thrombosis. All patients underwent anticoagulant therapy, and thrombus absorption took > 3 months in most patients. All patients were followed until October 2019, at which time 41 were asymptomatic and 2 had mild recurrent cough. SMPP with pulmonary consolidation (> 2/3 lobe) was the most strongly associated risk factor for thrombosis. Thrombosis-associated symptoms may be subtle, even absent. Elevated D-dimer, specifically > 11.1 mg/L (even > 5.0 mg/L), would assist in the early diagnosis of thrombosis. The long-term prognosis of thrombosis was good after timely administration of anticoagulant therapy.
Sections du résumé
BACKGROUND
BACKGROUND
With the increase of awareness of mycoplasma pneumoniae pneumonia (MPP), we found thrombosis in severe MPP (SMPP) was not rare. The aim of the study was to investigate the clinical characteristics, treatment, and long-term prognosis of MPP-associated thrombosis.
METHODS
METHODS
We retrospectively reviewed the medical records of 43 children with MPP-associated thrombosis between January 2013 and June 2019 at Beijing Children's Hospital. The results of blood coagulation studies, autoimmune antibody, thrombophilia screening, contrast-enhanced lung computed tomography, echocardiography, and blood vessel ultrasonography were analyzed, as were treatment outcomes.
RESULTS
RESULTS
Forty-two patients were diagnosed with SMPP. D-dimer was higher than 5.0 mg/L in 58.1% (25/43) of patients. The mean D-dimer level was 11.1 ± 12.4 mg/L. Anticardiolipin-IgM was positive in 60.0% of patients, β2-glycoprotein-IgM in 64.0%, and lupus anticoagulant in 42.1%. Chest imaging revealed pulmonary consolidation with lobe distribution in all patients (2/3-1 lobe in 10 patients, > 1 lobe in 29 patients). In our experience, thrombosis can occur in a vessel of any part of the body, and it can be initially detected as late as 31 days after disease onset. Thrombosis in the brain and abdomen can occur early, at 5 days after disease onset. Pulmonary vessels were the most commonly involved sites in the current study, and accordingly chest pain was the most common symptom (32.6%), followed by neurological symptoms (14.0%) and abdominal pain (9.3%). Thirty-five percent of patients were asymptomatic with regard to thrombosis. All patients underwent anticoagulant therapy, and thrombus absorption took > 3 months in most patients. All patients were followed until October 2019, at which time 41 were asymptomatic and 2 had mild recurrent cough.
CONCLUSIONS
CONCLUSIONS
SMPP with pulmonary consolidation (> 2/3 lobe) was the most strongly associated risk factor for thrombosis. Thrombosis-associated symptoms may be subtle, even absent. Elevated D-dimer, specifically > 11.1 mg/L (even > 5.0 mg/L), would assist in the early diagnosis of thrombosis. The long-term prognosis of thrombosis was good after timely administration of anticoagulant therapy.
Identifiants
pubmed: 31948402
doi: 10.1186/s12879-020-4774-9
pii: 10.1186/s12879-020-4774-9
pmc: PMC6966865
doi:
Substances chimiques
Antibodies, Anticardiolipin
0
Anticoagulants
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Subventions
Organisme : Beijing Municipal and Commission Health and Family Planning
ID : 2015-3-076
Références
Zhonghua Er Ke Za Zhi. 2014 Mar;52(3):172-6
pubmed: 24824385
Pediatrics. 1981 Mar;67(3):373-5
pubmed: 7243475
Postgrad Med J. 1990 May;66(775):356-62
pubmed: 2371184
Front Pediatr. 2018 Oct 26;6:296
pubmed: 30416990
Nature. 2017 Apr 6;544(7648):105-109
pubmed: 28329764
Korean J Pediatr. 2015 Jun;58(6):211-7
pubmed: 26213549
Zhonghua Er Ke Za Zhi. 2018 Dec 2;56(12):950-951
pubmed: 30518011
Pediatr Pulmonol. 2008 Feb;43(2):200-2
pubmed: 18041082
Adv Respir Med. 2018 Dec 30;:null
pubmed: 30594998
Vasa. 2007 Nov;36(4):267-74
pubmed: 18357919
BMC Infect Dis. 2017 Jun 7;17(1):402
pubmed: 28592263
Interact Cardiovasc Thorac Surg. 2010 Dec;11(6):849-51
pubmed: 20847069
J Clin Med. 2019 May 22;8(5):null
pubmed: 31121867
Pediatr Pulmonol. 1997 May;23(5):375-81
pubmed: 9168512
Front Pediatr. 2017 Aug 10;5:170
pubmed: 28848725
J Child Neurol. 2002 Jan;17(1):55-7
pubmed: 11913573
Physiol Rev. 2013 Jan;93(1):327-58
pubmed: 23303912
Physiol Rev. 2016 Oct;96(4):1211-59
pubmed: 27489307
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Respir Res. 2019 Aug 23;20(1):193
pubmed: 31443650
Eur Respir J. 2012 Oct;40(4):886-94
pubmed: 22267767
Sci Rep. 2017 Aug 16;7(1):8478
pubmed: 28814783
Am J Emerg Med. 2018 Sep;36(9):1613-1618
pubmed: 29371044
Thorax. 2009 Jul;64(7):587-91
pubmed: 19131448
Zhonghua Er Ke Za Zhi. 2012 Dec;50(12):915-8
pubmed: 23324149
J Infect Chemother. 2019 Apr;25(4):281-284
pubmed: 30270004
Pediatr Infect Dis J. 2011 Sep;30(9):740-4
pubmed: 21852763
Clin Infect Dis. 2001 May 1;32(9):1281-9
pubmed: 11303262
Zhonghua Jie He He Hu Xi Za Zhi. 2011 Nov;34(11):832-6
pubmed: 22333470
Allergy Asthma Immunol Res. 2014 Jan;6(1):22-6
pubmed: 24404389
Lancet Infect Dis. 2001 Dec;1(5):334-44
pubmed: 11871806
Blood Adv. 2018 Nov 27;2(22):3292-3316
pubmed: 30482766
Pediatr Pulmonol. 2006 Mar;41(3):263-8
pubmed: 16437541
Zhonghua Er Ke Za Zhi. 2017 Sep 2;55(9):705-706
pubmed: 28881519
Exp Ther Med. 2018 Dec;16(6):5025-5030
pubmed: 30546408
Pediatrics. 2007 Jan;119(1):e292-5
pubmed: 17178923
Clin Infect Dis. 2001 Nov 15;33(10):E119-21
pubmed: 11595996
J Child Neurol. 2009 Jul;24(7):891-4
pubmed: 19617462
Zhonghua Er Ke Za Zhi. 2013 Oct;51(10):745-52
pubmed: 24406226